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MEDICATION FACTORS
Legitimate use
“…muscle relaxants in situations…like 
whiplash and torticollis, where they 
have acute muscle spasm” (GP07)
…
Effective medication
“…wish they didn’t exist on the 
market…in many ways, they’re too 
good” (GP01)
PROFESSIONAL FACTORS
Continuation from previous prescribers
“…my other doctor gave me these and 
there was no problem and they were 
great and what are you talking about 
now” (GP07)
Lack of alternatives
“…in the real world of general practice 
the pressure on a general practitioner 
to prescribe is almost always 
driven…by the lack of alternative 
support therapies” (GP05)
PATIENT FACTORS
Patient threats
“I’ll go out of here and I’ll have a seizure and 
it’ll be on your head doctor” (GP03)
Eliciting sympathy
“…just tell him…you're feeling depressed or 
feeling suicidal, you can't sleep. Just tell him 
that and he'll…write you the script” (YC09)
Doctor shopping
“3 or 4 doctors…what we find here is that 
you'll have a gang, say 4 or 5 people like. 
They'll all have scripts” (YC09)
Patient education
“…datasheets need to be…simplistic not legalistic…this 
is a habit-forming drug…this drug will…work less 
every time you use it. Why not talk to your 
pharmacist or your doctor about it” (GP04)
Alternatives
“I think if there was a therapist within 
each practice, it might prevent the…high 
level of prescribing of benzos” (YC03)
• 7 days of continuous BZD use can lead to dependence in children4
AIM: Describe the challenges of deprescribing BZDs for young chronic BZD patients in the community
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BACKGROUND METHODS
RESULTS
CONCLUSIONS
• Local ethical committee approval 
obtained 
• Semi-structured interviews occurred 
between June and December 2013
• 50% increase in benzodiazepine (BZD) misuse amongst European 15-16 year-olds, 2003 – 20111,2
• 3% of young people misused BZDs in Ireland in 20113
• Impaired perception of risks in adolescent decision-making due to incomplete neurological development5
General Practitioners (GPs): collaborate with 
patients to use BZDs appropriately
Youth Counsellors (YCs):  can maturely reflect
patient perspective in GP consultations
RATIONALE: Both observe patterns of behaviour of which the other might not be aware
PRESSURE TO PRESCRIBE
• GPs and YCs identified different factors about BZD use in young patients
• Reductions in BZD usage will only succeed through co-operation between all stakeholders including patients, the medical profession, regulators, 
and the government
• Further research should be conducted to assess the patient benefits and monetary benefits of BZD reduction interventions
Interviewee Demographics
Profession GP: 7 | YC: 10
Gender M: 9 | F: 8
Age (yrs) ≤40: 7 | >40: 10
Experience (yrs) ≤10: 6 | >10: 11
Restrictions
“…make the availability of 
benzodiazepines…much harder” (GP02)
ALLEVIATING FACTORS
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